Proactive Investors - Run By Investors For Investors

PharmaCielo acquires global cannabis company Creso Pharma in multimillion-dollar deal

The combined company is poised to become a global powerhouse in the medicinal cannabis industry, says PharmaCielo's CEO
dollar sign on cannabis
The Toronto-based company is the Canadian parent of a Colombian cultivator and producer of medicinal-grade cannabis oil

PharmaCielo Ltd (CVE:PCLO) has acquired Australian cannabis company Creso Pharma in a A$122 million deal that will expand its global reach.

The Toronto-based company is the Canadian parent of a Colombian cultivator and producer of medicinal-grade cannabis oil.

Shares of PharmaCielo fell on Thursday afternoon, sitting 8.5% lower at C$7.45.

READ: Buds & Duds: Cannabis stocks continue to tumble but ICC International Cannabis shares soar on deal to acquire VendaPharm

Creso Pharma is a global medicinal cannabis company specializing in research, development and production of therapeutic, nutraceutical and animal health products.

Under the terms of the acquisition, PharmaCielo will pay A$0.63 per Creso Pharma share, a 50% premium over the closing price on May 31. PharmaCielo will issue shares to Creso Pharma priced at C$7.6166 per share, an exchange ratio of 0.0775 PharmaCielo shares per each Creso Pharma share.

The acquisition creates a combined company that is poised to become a “global powerhouse” in the medicinal cannabis industry, according to David Attard, CEO of PharmaCielo.    

"The acquisition affords us the opportunity to bring our high-quality Colombian oil production to market immediately and expand into higher-margin, branded product sales faster by harnessing the expertise of a proven and highly engaged commercialization team possessing both an immediately available product portfolio and active international sales channels," Attard said in a statement.

Global footprint

The combined company will quadruple its global footprint with presence in more than a dozen countries spanning North and Latin America, Switzerland, Europe, the Middle East, Australia and New Zealand, according to PharmaCielo’s Attard.

"The quality and scale of PharmaCielo's cultivation and oil extraction operations in Colombia complements our focus on meeting global demand for the highest quality CBD and THC based therapeutic, nutraceutical and animal health products through increased access to the necessary quality and volume of oil production," said Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma.

Both boards and shareholders of Creso and PharmaCielo have approved the deal. The companies now await the go-ahead from the TSX Venture Exchange and the Australian Securities and Investment Commission, as well as Australian Court approval.

--Updates share price--

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full PCLO profile View Profile

PharmaCielo Timeline

Related Articles

cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.
A visual representation of a drug candidate working in a dog
January 28 2019
The company has reaffirmed its upcoming milestones as it confirmed December quarter achievements.
cannabis plant
Mon
The company recently underwent a brand identity redesign and unveiled a new wknd! product line consisting of pre-rolls, vape pens and cannagars which it will launch in July in Washington State
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use